メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・血液内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(5)
研究成果
(185)
フィンガープリント
医学部・血液内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Nonhodgkin Lymphoma
78%
Diffuse Large B Cell Lymphoma
76%
Chemotherapy
69%
Remission
69%
Acute Myeloid Leukemia
67%
Neoplasm
40%
Etoposide
37%
Survival Rate
35%
Disease Free Survival
34%
Overall Survival
33%
Disease
32%
Progression Free Survival
29%
Clinical Trial
29%
Leukemia
27%
Retrospective Study
27%
B Cell Lymphoma
26%
Mantle Cell Lymphoma
25%
Infection
25%
Large Cell Lymphoma
25%
Febrile Neutropenia
25%
Hodgkin Disease
25%
Myelodysplastic Syndrome
25%
Dexamethasone
25%
Granulocyte Colony Stimulating Factor
25%
Pharmacokinetics
25%
Chronic Myeloid Leukemia
25%
Asciminib
25%
Antiproliferative Activity
20%
Malignant Neoplasm
19%
Doxorubicin
19%
Vincristine
19%
Hematologic Malignancy
17%
Colorectal Cancer
17%
Bosutinib
17%
Prednisolone
17%
Chemotherapy Regimens
16%
Cyclophosphamide
16%
Cytochrome C
16%
Nucleoside Diphosphate Kinase A
15%
Bleomycin
15%
Follicular Lymphoma
15%
Acute Leukemia
14%
Caspase
14%
Interleukin 6
13%
Combination Therapy
13%
Tumor Lysis Syndrome
12%
Cytarabine
12%
Bleeding
12%
Vasculotropin
12%
Two-Photon Microscopy
12%
Bortezomib
12%
Piperacillin Plus Tazobactam
12%
Burkitt's Lymphoma
12%
Bloodstream Infection
12%
Nucleolysin TIA 1 Isoform P40
12%
Hospital Infection
12%
Circulating Tumor DNA
12%
Promyelocytic Leukemia
12%
Syndrome
12%
Micafungin
12%
Ruxolitinib
12%
Carboplatin
12%
Antifungal Therapy
12%
Biological Marker
12%
Vibrio vulnificus
12%
Caffeic Acid
12%
Solanum Torvum
12%
Ravulizumab
12%
Paroxysmal Nocturnal Hemoglobinuria
12%
Janus Kinase
12%
Seminoma
12%
Multiple Myeloma
12%
Anthraquinone
12%
Immunocompromised Patient
12%
Ifosfamide
12%
Hemopoietic Growth Factor
12%
Brentuximab Vedotin
12%
Pembrolizumab
12%
Azacitidine
12%
Mycosis
12%
Imatinib
12%
Emetine
12%
Thrombocythemia
12%
Core Binding Factor Beta
12%
Community Acquired Infection
12%
Antiinflammatory Activity
12%
Lenalidomide
12%
Zinc Finger and BTB Domain Containing Protein 16
12%
Retinoic Acid Receptor
12%
Promyelocytic Leukemia Protein
12%
Protein Tyrosine Kinase Inhibitor
12%
Cefodizime
12%
Thrombomodulin
12%
Benzodiazepine
12%
Blood Clotting Factor 6
12%
Hepatitis C Virus
12%
Clinical Study
12%
Adverse Event
11%
Daunorubicin
11%
Medicine and Dentistry
Acute Myeloid Leukemia
76%
Diffuse Large B-Cell Lymphoma
66%
Rituximab
64%
Prognostic Factor
45%
Retrospective Study
44%
Overall Survival
43%
Myelodysplastic Syndrome
40%
Hematology
38%
Non-Hodgkin Lymphoma
36%
Leukemia
36%
B Cell
34%
Leukemia Cell
33%
Disease
32%
Elderly Patient
31%
Clinical Trial
29%
Chronic Myelogenous Leukemia
28%
T Cell
27%
Induction Chemotherapy
26%
Disease Free Survival
26%
Neoplasm
26%
Mantle Cell Lymphoma
25%
Large-Cell Lymphoma
25%
Febrile Neutropenia
25%
B-Cell Lymphoma
25%
Bleeding
25%
T Lymphocyte Receptor
25%
Imaging of Bone
25%
Immunoglobulin Light Chain
25%
Heavy Chain
25%
Human Leukocyte Antigen
25%
Subgroup Analysis
25%
Asciminib
25%
Peripheral Neuropathy
20%
Cancer
20%
Progression Free Survival
19%
Imaging Technique
18%
Drug Resistance
18%
Survival Rate
18%
Programmed Cell Death
17%
Bosutinib
17%
Central Nervous System
16%
Chemotherapy Regimens
16%
Chromosome Aberration
16%
Two-Photon Microscopy
16%
Cytarabine
16%
Lymphoma Cell
16%
Allogenic Bone Marrow Transplantation
15%
Immunoglobulin A
15%
Immunoglobulin
15%
Dasatinib
15%
Nilotinib
15%
Tyrosine-Kinase Inhibitor
15%
Hematologic Malignancy
14%
Symptom
14%
Factor Analysis
14%
Virus DNA
14%
Immunotherapy
14%
Clinical Significance
14%
Myeloid Leukemia
13%
Multivariate Analysis
13%
Hazard Ratio
12%
Epstein Barr Virus
12%
Mantle Cell Lymphoma International Prognostic Index
12%
Hepatitis B
12%
Hepatitis B Virus
12%
Leukemia Relapse
12%
Bortezomib
12%
Bone Marrow Transplantation
12%
Waldenström's Macroglobulinemia
12%
Dexamethasone
12%
Whole Body Radiation
12%
Monosomy 7
12%
Essential Thrombocythaemia
12%
Duodenum Ulcer
12%
Bone Marrow Microenvironment
12%
Hematopoietic Stem Cell
12%
Bloodstream Infection
12%
Fibroblast Growth Factor 2
12%
PI3K/AKT Pathway
12%
Immunocompromised Patient
12%
Primary Central Nervous System Lymphoma
12%
Disease Burden
12%
Nucleic Acid Amplification
12%
Symptomatic Treatment
12%
Acute Promyelocytic Leukemia
12%
Tooth Extraction
12%
Factor VII
12%
Multiphoton Microscopy
12%
Fluorouridine
12%
Tumor Lysis Syndrome
12%
Transcription Factor EZH2
12%
Histone H3
12%
Hepatitis C Virus
12%
Lysine
12%
Polycythemia vera
12%
Ravulizumab
12%
Janus Kinase
12%
Pharmacokinetics
12%
Deferasirox
12%
Pure Red Cell Aplasia
12%
Keyphrases
Acute Myeloid Leukemia
45%
Myelodysplastic Syndrome
27%
Leukemia Cells
26%
Intravascular Large B-cell Lymphoma (IVLBCL)
25%
Hematology
25%
Lymphoma Patients
24%
Unselected Patients
18%
Induction Chemotherapy
18%
Confidence Interval
17%
Treatment Results
16%
Lymphoma
16%
Non-Hodgkin Lymphoma
15%
Induction Therapy
15%
Extranodal
14%
Disease-free Survival
14%
D-index
13%
Diffuse Large B-cell Lymphoma (DLBCL)
13%
Central Nervous System Recurrence
13%
Complete Remission
13%
Retrospective Analysis
12%
Japan Clinical Oncology Group
12%
Rituximab-containing Chemotherapy
12%
Aggressive non-Hodgkin Lymphoma
12%
Secondary Leukemia
12%
Flow Cytometric
12%
Proliferative Effect
12%
Rolling Adhesion
12%
Dynamic Analysis
12%
Diagnostic Specimen
12%
Virus Pneumonia
12%
ILC2
12%
Monosomy 7
12%
DNA Detection
12%
Natural Killer T-cell Lymphoma
12%
Hematopoietic Function
12%
Vascular Endothelial Growth Factor
12%
Differentiation Syndrome
12%
COVID-19 mRNA Vaccination
12%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
12%
Oncogenetics
12%
Constant Region
12%
Font
12%
Rituximab Maintenance
12%
Indolent Lymphoma
12%
Third Harmonic Generation
12%
Nonlinear Optics
12%
Near-infrared Excitation
12%
Real-time Quantitative
12%
Bystander Cells
12%
High Tumor Burden
12%
Second Harmonic Generation
12%
International Journals
12%
Recombinant Activated Factor VII (rFVIIa)
12%
CRLF2
12%
Ruxolitinib
12%
Dental Extraction
12%
Febrile Neutropenia
12%
Interleukin-6
12%
Group Studies
12%
In Vitro Anticancer Activity
12%
Vibrio Vulnificus
12%
DNA Sources
12%
Cell-free DNA (cfDNA)
12%
Tumor DNA
12%
Flat Warts
12%
Solanum Torvum Swartz
12%
Multiphoton Excitation Microscopy
12%
Non-labeling
12%
Enhancer of Zeste Homolog 2 (EZH2)
12%
Methyl Caffeate
12%
H3K27me3
12%
Ravulizumab
12%
Hematological Diseases
12%
Liposomal Contrast Agent
12%
Upper Part
12%
ALK Expression
12%
Dendron
12%
NPM-ALK
12%
Magnetic Resonance Microimaging
12%
Cardiopulmonary Arrest
12%
Severe Infection
12%
Nanoparticle Distribution
12%
Macrophage Targeting
12%
Dexamethasone Palmitate
12%
Serum IgG Level
12%
R-CHOP Therapy
12%
System Restoration
12%
Gastroduodenitis
12%
Newly Diagnosed
12%
Successful Pregnancy
12%
Pure Red Cell Aplasia
12%
Deferasirox
12%
Cerebrospinal Fluid
12%
Plasma Epstein-Barr Virus DNA
12%
Epipharynx
12%
Combination Therapy
12%
Mitoxantrone
12%
Angioimmunoblastic
12%
Predictive Significance
12%
Adult T-cell Lymphoma
12%